RNASET2 Modulation for Genetically Stratified IBD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug development strategies for inflammatory bowel disease (IBD) are suboptimal due to the lack of targeted therapeutics and predictive biomarkers, with Ribonuclease T2 (RNASET2) being identified as a potential therapeutic target but its functional role in IBD pathogenesis remaining unclear.
Innovation Solution
Therapeutic agents are developed to modulate RNASET2 activity or expression based on genetic risk variants, such as Indel 1 and specific SNPs, to treat or prevent IBD by administering modulators or inhibitors, including antibodies and recombinant proteins, to enhance or decrease RNASET2 and TNF Superfamily Member 15 (TL1A) activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current drug development strategies are used for IBD, then general treatment approaches are applied, but treatment precision and effectiveness are insufficient due to lack of targeted therapeutics and predictive biomarkers
Solution Approach 1:
The patent segments the heterogeneous IBD patient population into distinct subgroups based on genetic risk variants at the RNASET2 gene locus. By dividing patients into those with and without specific genetic markers, the invention enables targeted treatment strategies for each subgroup, improving treatment precision while managing development complexity through focused approaches.
Solution Approach 2:
The patent performs preliminary genetic testing to identify patients with risk variants at the RNASET2 locus before initiating treatment. This preliminary action of genotyping allows for early stratification and selection of appropriate therapeutic interventions, enabling precision medicine approaches in the drug development process.
2Reliability
If RNASET2 is targeted as a therapeutic approach, then treatment effectiveness may be improved for specific patient subsets, but the functional role and mechanism of RNASET2 in IBD pathogenesis remain unclear
Solution Approach 1:
The patent incorporates feedback loops where treatment responses are monitored and used to refine understanding of RNASET2's functional role. By observing clinical outcomes in patients with known genetic variants and adjusting therapeutic strategies accordingly, the invention simultaneously improves treatment effectiveness and generates mechanistic insights through iterative learning.
Solution Approach 2:
The patent uses genetic risk variants at the RNASET2 locus as intermediary markers that bridge the gap between unknown molecular mechanisms and observable clinical outcomes. These genetic markers serve as proxies that enable targeted treatment development even while the complete functional pathway remains to be fully elucidated.
3Measurement precision
If genetic risk variants at RNASET2 are used for patient stratification, then predictive biomarker capability is enhanced, but identification of appropriate therapeutic targets for patient-specific strategies remains challenging
Solution Approach 1:
The patent develops a universal therapeutic approach targeting the RNASET2 pathway that can be applied across multiple IBD subgroups identified by genetic stratification. By creating a multi-functional treatment strategy that addresses the common underlying mechanism in genetically-defined subgroups, the invention enhances both biomarker predictive capability and therapeutic adaptability simultaneously.
Data Source
AI summary
Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of a disease or condition in a subject. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with a modulator of RNASET2, as described herein.